Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma

Oncology

Volumn 78, Issue 5-6, 2010, Pages 389-393

  Abaid, Lisa N ^a   Goldstein, Bram H ^a   Micha, John P ^a   Rettenmaier, Mark A ^a   Brown III, John V ^a   Markman, Maurie ^b  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carboplatin; Chemotherapy; Gemcitabine; Overall survival; Paclitaxel; Progression free survival

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HUMAN; LONG TERM CARE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; CANCER STAGING; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FOLLOW UP; MORTALITY; NEUROLOGIC DISEASE; OVARIAN NEOPLASMS; PATHOLOGY; SURVIVAL RATE;

ANEMIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM STAGING; NERVOUS SYSTEM DISEASES; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 77956065159     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320579     Document Type: Article

References (20)

1. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.
2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke- Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
3. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/ paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
4. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE: A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. North Thames Ovary Group Study. Ann Oncol 1997; 8: 327-333.
5. Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, Chapman D, Almadrones L, Lewis JL Jr: Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992; 45: 284-289.
6. Bertelsen K, Jakobsen A, Stroyer J, Nielsen K, Sandberg E, Andersen JE, et al: A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group (DACOVA) trial. Gynecol Oncol 1993; 49: 30-36.
7. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-2465.
8. Micha JP, Goldstein BH, Mattison JA, Bader K, Graham C, Rettenmaier MA, Brown JV, Markman M: Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol Oncol 2005; 96: 132-135.
9. Juretzka MM, Barakat RR, Chi DS, et al: CA125 level as a predictor of progressionfree survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 2007; 104: 176-180.
10. Micha JP, Goldstein BH, Rettenmaier MA, Brown JV 3rd, John CR, Markman M: Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma. Int J Gynecol Cancer 2009; 19: 239-241.
11. Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, Alberts D: Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m 2 ) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 2009; 114: 195-198.
12. Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, et al: Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol 2009; 27: 4642-4648.
13. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS: The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 2008; 108: 276-281.
14. Micha JP, Goldstein BH, Rettenmaier MA, Mattison J, Graham C, Birk CL, Brown JV: Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer. Gynecol Oncol 2004; 94: 719-724.
15. Vergote I, Rustin GJS, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MKB, et al: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2000; 92: 181534-181535.
16. Lee SJ, Lee JW, Min JA, Park CS, Kim BG, Lee JH, Bae DS: A pilot study of three-cycle consolidation chemotherapy with paclitaxel and platinum in epithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy. Int J Gynecol Cancer 2006; 16: 95-100.
17. Disilvestro PA, Fisher M, Pearl ML, Buhl A, Chalas E, Valea FA: Pilot phase 2 trial of 4 months of maintenance pegylated liposomal doxorubicin in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy. Gynecol Obstet Invest 2006; 63: 1-6.
18. McGuire WP: Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates. J Clin Oncol 2009; 27: 4633-4634.
19. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S: Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003; 90: 390-396.
20. Gadducci A, Katsaros D, Zola P, Scambia G, Ballardini M, Pasquini E, et al: Weekly lowdose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at secondlook surgery after 6 cycles of paclitaxel/ platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2). Int J Gynecol Cancer 2009; 19: 615-619.